FIGURE 4.

The relationship between the number of genomic alterations detected prior to treatment with osimertinib and the therapeutic response to osimertinib is shown. Six patients, out of 54 among whom NGS was technically successful, were excluded from the analysis because of discontinuation due to adverse effects or patient's request. (A) The number of oncogenic SNVs and Indels including VUS. (B) The sum of SNVs/indels and CNV including VUS. (C) The sum of SNVs/indels and CNV excluding VUS. Non‐responders and responders had PFS of 90 days or less, and more than 90 days, respectively. Comparisons between non‐responders and responders were made with the nonparametric Mann–Whitney U test. SNV/Indel, single‐nucleotide variants and/or insertion/deletions; CNV, copy number variants; VUS, variants of unknown significance